ASND Ascendis Pharma A/S
Healthcare
Close 10/9
- Open
- 225.08
- High
- 233.96
- Low
- 223.96
- Prev close
- 222.69
- Volume
- 761K
Is Ascendis Pharma A/S a buy? Fundamentals and valuation first
As of 2026-10-09
Quality: Good, Growth: Strong, Risk / liquidity: Good.
Quality Good ROE, TTM is Top; Operating margin, TTM is Good.
Growth Strong Revenue growth, TTM YoY is Top.
Momentum Neutral 240-day return is Good, but 60-day return is Average.
Risk / liquidity Good 20-day dollar volume is Top; 60-day annualized volatility is Good.
Ascendis Pharma A/S (ASND) peers and tracking
This page refreshes daily after the close. Add Ascendis Pharma A/S to your watchlist to track signal changes on your next visit.
Ascendis Pharma A/S (ASND) quant signal backtests
Market-wide momentum baseline
Across 98,394 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.23%, a 57.8% positive-return rate, and +2.88 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
More history: Signals not active now
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
52-week adjusted-price high
PendingAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
28 times historically; 60-day forward avg +3.74%, win rate 53.6%, beating the market by -0.04 pts on average.
Top-quintile 6-month momentum
PendingThe stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
24 times historically; 60-day forward avg +9.58%, win rate 58.3%, beating the market by +5.77 pts on average.
Filed revenue acceleration
PendingTTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
12 times historically; 60-day forward avg +12.67%, win rate 66.7%, beating the market by +9.58 pts on average.
Continue researching Ascendis Pharma A/S with the evidence above.
Continue in Studio ↗Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
- This is an American depositary receipt (ADR). The data does not say how many ordinary shares each ADR represents, so per-share and market-value metrics (P/E, price/book, free-cash-flow yield, EPS growth and earnings surprises) are not computed.
- ADRs listed on NYSE or NASDAQ are covered as a separate group selected by dollar volume, in addition to the common-stock universe; the 6-month momentum signal ranks each ADR against the liquid US common stocks.
- Financial statements are reported in EUR. Operating margin, ROE and revenue growth are computed within EUR; no figure divides the USD share price by EUR amounts.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.